Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS after Sanofi made the drug available at a discount under the patient ...

U.S. President Donald Trump will meet on Thursday with chief executives from major drugmakers, a White House official ...

Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share purchase agreement with buyer Clayton Dubilier & Rice (CD&R).

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025. Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the ...

L’Oréal remains an important shareholder of Sanofi and is fully supportive of the company’s value creation strategy,” said L’Oréal. “The transaction will optimize L ...

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €120.00. The ...

French pharma major Sanofi’s saw its shares edge up 1% by early afternoon, despite announcing a disappointment for a vaccine ...

Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for ...

An estimated 5,900 new cases of MM, an incurable cancer of the blood plasma cells, are diagnosed in the UK every year. Administered as an intravenous infusion, Sanofi’s Sarclisa is designed to bind to ...